-
-
-
-
-
-
-
Ipsen Presents Phase III NAPOLI 3 Trial of Onivyde® Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma at ASCO GI
-
-
-
-
-
-
-
Ipsen: ESMO 2021: Cabometyx® Demonstrates Sustained 78% Reduction in Risk of Disease Progression or Death in People Living With Uncommon Form of Thyroid Cancer
-
-
-
-
-
67,391 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

